Whole-target Consolidation Therapy Under Systemic Therapy for Oligometastatic Nasopharyngeal Carcinoma
Status:
Recruiting
Trial end date:
2026-06-20
Target enrollment:
Participant gender:
Summary
In this exploratory clinical trial, patients with newly diagnosed distant metastatic
nasopharyngeal carcinoma were treated with gemcitabine+ cisplatin+PD-1 inhibitor regimen
followed by whole-target radiotherapy (IMRT for local regional lesion, SBRT for distant
metastasis) and PD-1 inhibitor long-term maintenance regimen. To investigate the efficacy and
safety of "whole target" radiotherapy combined with immuno-maintenance therapy.